ArticleCancer immunology, immunotherapy : CII2025

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.

Camillo Porta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.